within Pharmacolibrary.Drugs.ATC.L;

model L01FX20
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.666666666666667e-06,
    adminDuration  = 600,
    adminMass      = 15 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00513,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00467,
    k12             = 0.31,
    k21             = 0.31
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01FX20</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tremelimumab is a fully human monoclonal antibody that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), an immune checkpoint inhibitor. It is designed to enhance antitumor immune responses by blocking CTLA-4–mediated downregulation of T cell activation. Tremelimumab has been studied in various cancers, including malignant mesothelioma and melanoma, but as of 2024 it is not widely approved for clinical use except in specific indications (e.g., in combination with durvalumab for unresectable hepatocellular carcinoma in some jurisdictions).</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult patients with advanced solid tumors or malignant mesothelioma following intravenous administration.</p><h4>References</h4><ol><li><p>Rini, BI, et al., &amp; Gordon, M (2011). Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. <i>Cancer</i> 117(4) 758–767. DOI:<a href=&quot;https://doi.org/10.1002/cncr.25639&quot;>10.1002/cncr.25639</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20922784/&quot;>https://pubmed.ncbi.nlm.nih.gov/20922784</a></p></li><li><p>Falchook, GS, et al., &amp; Peterson, DA (2021). A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors. <i>Investigational new drugs</i> 39(5) 1284–1297. DOI:<a href=&quot;https://doi.org/10.1007/s10637-021-01088-4&quot;>10.1007/s10637-021-01088-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33852104/&quot;>https://pubmed.ncbi.nlm.nih.gov/33852104</a></p></li><li><p>Millward, M, et al., &amp; Mather, CB (2013). Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours. <i>British journal of cancer</i> 108(10) 1998–2004. DOI:<a href=&quot;https://doi.org/10.1038/bjc.2013.227&quot;>10.1038/bjc.2013.227</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23652314/&quot;>https://pubmed.ncbi.nlm.nih.gov/23652314</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01FX20;
